What is GenoME Diagnostics?
Headquartered in Belfast, Northern Ireland, GenoME Diagnostics operates as a specialized spinout from Queen's University. The company is dedicated to the development of novel blood tests designed to facilitate the earlier and more accurate diagnosis of ovarian cancer. By leveraging academic research to address critical gaps in oncology screening, GenoME Diagnostics occupies a high-growth niche within the life sciences market. Its core value proposition lies in the ability to provide actionable clinical data that can significantly improve patient outcomes through timely intervention, positioning the firm as a key innovator in the diagnostic landscape.
How much funding has GenoME Diagnostics raised?
GenoME Diagnostics has raised a total of $2M across 2 funding rounds:
Angel/Seed
$424K
Other Financing Round
$1.6M
Angel/Seed (2021): $424K with participation from QUBIS, Deepbridge Capital, and Co-Fund NI
Other Financing Round (2023): $1.6M led by QUBIS and Deepbridge Capital
Key Investors in GenoME Diagnostics
QUBIS
QUBIS Ltd collaborates with academic entrepreneurs to transform high-quality research from Queens University, Belfast into commercially viable spinoff companies. They focus on sectors such as digital, life sciences, and environmental technologies.
Deepbridge Capital
Deepbridge Syndicate is a private investor network that caters to experienced investors and family offices, allowing them to create personalized portfolios of innovative Life Sciences and Technology companies.
Co-Fund NI
Co-Fund NI is a venture capital fund that provides equity financing to high-growth potential small and medium-sized enterprises based in Northern Ireland.
What's next for GenoME Diagnostics?
With the recent infusion of capital, GenoME Diagnostics is well-positioned to accelerate its clinical validation studies and scale its operational infrastructure. The strategic roadmap likely involves expanding its intellectual property portfolio and navigating the regulatory pathways necessary for commercial deployment. As the company moves beyond its initial seed-stage foundations, the focus will shift toward establishing partnerships with healthcare providers and diagnostic laboratories. This growth trajectory suggests a move toward broader market penetration, aiming to integrate its diagnostic solutions into routine clinical workflows to address the urgent global demand for more effective cancer screening tools.
See full GenoME Diagnostics company page
